ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Development and validation of a transformer-based deep learning model for predicting distant metastasis in non-small cell lung cancer using
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation.Frontiers in medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to develop and validate a hybrid deep learning (DL) model that integrates convolutional neural network (CNN) and vision transformer (ViT) architectures to predict distant metastasis (DM) in patients with non-small cell lung cancer (NSCLC) using
methodsA retrospective analysis was conducted on a cohort of consecutively registered patients who were newly diagnosed and untreated for NSCLC. A total of 167 patients with available PET/CT images were included in the analysis. DL features were extracted using a combination of CNN and ViT architectures, followed by feature selection, model construction, and evaluation of model performance using the receiver operating characteristic (ROC) and the area under the curve (AUC).
resultsThe ViT-based DL model exhibited strong predictive capabilities in both the training and validation cohorts, achieving AUCs of 0.824 and 0.830 for CT features, and 0.602 and 0.694 for PET features, respectively. Notably, the model that integrated both PET and CT features demonstrated a notable AUC of 0.882 in the validation cohort, outperforming models that utilized either PET or CT features alone. Furthermore, this model outperformed the CNN model (ResNet 50), which achieved an AUC of 0.752 [95% CI 0.613, 0.890], p < 0.05. Decision curve analysis further supported the efficacy of the ViT-based DL model.
conclusionThe ViT-based DL developed in this study demonstrates considerable potential in predicting DM in patients with NSCLC, potentially informing the creation of personalized treatment strategies. Future validation through prospective studies with larger cohorts is necessary.
Indexed as
Identifiers
40779149What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.